New pill HRS-7085 aims to tame ulcerative colitis
NCT ID NCT07229950
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 2 trial tests an experimental pill called HRS-7085 in 48 adults with moderate to severe ulcerative colitis. Participants receive either a low dose, high dose, or placebo for several weeks. The study checks for safety, symptom improvement, and how the drug moves through the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HRS-7085 tablets
- What this could lead to
- If successful, this could lead to a new oral treatment option to control ulcerative colitis symptoms and reduce inflammation.
- What could go wrong
- This is an early phase 2 trial with only 48 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
West China Hospital of Sichuan University
RECRUITINGChengdu, Sichuan, 610044, China
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.